After just a year in the role of chief medical officer and head of global clinical development at Californian biotech BioMarin (Nasdaq: BMRN), Harold Bernstein has taken a new job elsewhere.
Dr Bernstein has been named president, head of R&D and chief medical officer at Maze Therapeutics, a company translating genetic insights into new precision medicines.
Maze, which is based across the bridge from BioMarin in South San Francisco, has also promoted Eric Green, formerly the firm’s senior vice president, research and translational sciences, to the role of chief scientific officer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze